SSRIs for Management of Menopausal Vasomotor Symptoms

First‑Line SSRI Options

Paroxetine 10–20 mg daily, citalopram 10–30 mg daily, or escitalopram 10–20 mg daily reduce hot‑flash frequency and severity by approximately 50–60 % in menopausal women. [1][2]
Paroxetine at 10–20 mg daily achieves a 62–65 % reduction in composite hot‑flash scores, indicating the highest efficacy among first‑line agents. [3][4]
Citalopram (10–30 mg) provides efficacy comparable to paroxetine and yields a 50 % reduction in hot‑flash scores versus 36 % with placebo. It is the preferred alternative when tamoxifen is being used because it does not inhibit CYP2D6. [1][2][4][3]
Escitalopram (10–20 mg) is effective for vasomotor symptoms with a favorable side‑effect profile. [1][2]6

Fluoxetine produces a 50 % reduction in hot‑flash scores but shows marked response variability (42 % achieve >50 % improvement, 27 % experience worsening). It should be avoided in patients on tamoxifen due to CYP2D6 inhibition. [4][1]2
Sertraline shows mixed results at 50–100 mg; it is superior to placebo in tamoxifen users but less effective than paroxetine, citalopram, or escitalopram. Consider only as a second‑line option. 4

Initiate therapy with the lowest effective dose and titrate based on clinical response; most women notice improvement within the first week, which is faster than the antidepressant effect of SSRIs. [6][4]
Overall, SSRIs reduce vasomotor symptoms by 50–60 % compared with a 30 % response to placebo, providing meaningful relief though less effective than estrogen therapy. [1][2]6

Moderate‑certainty evidence (National Comprehensive Cancer Network) identifies the most common adverse effects: nausea, dry mouth, decreased appetite, constipation, sexual dysfunction, and insomnia. [4][7]5
Approximately 10–20 % of women discontinue SSRIs because of side effects; adverse events are dose‑related and less frequent at lower doses. 4
Gradual tapering is recommended when discontinuing an SSRI to avoid withdrawal symptoms. [5][4]

SSRIs are appropriate for women who cannot use hormone therapy; they provide comparable vasomotor relief. [1][2]8
Paroxetine and fluoxetine should be avoided in patients receiving tamoxifen; citalopram, escitalopram, or venlafaxine are preferred alternatives. [3][8][5][9]
Although paroxetine inhibits CYP2D6, current evidence shows no adverse impact on breast‑cancer outcomes. [1][2]

SSRIs may be selected when vasomotor symptoms coexist with depressive symptoms, offering dual therapeutic benefit. [10][11]
For sleep disturbance associated with hot flashes, adding zolpidem 5–10 mg can be considered. [1][10]
Sexual dysfunction is a recognized SSRI side effect and may exacerbate menopausal sexual symptoms. 10

Head‑to‑head trials are limited; no single SSRI has demonstrated superiority over the others for vasomotor symptom control. [1][2]
All effective SSRIs show similar efficacy in breast‑cancer survivors as in the general menopausal population. 6

SNRIs (venlafaxine 75 mg or desvenlafaxine 100 mg) achieve a 50–60 % reduction in vasomotor symptoms, comparable to SSRIs. [1][2]6
Gabapentin 300–900 mg taken at night is useful for hot flashes that disturb sleep. [1][2]8
Cognitive‑behavioral therapy reduces the bother and impact of vasomotor symptoms and can be used as an adjunct or alternative. [1][2]